Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
53,512,954,839
-
Total 13F shares
-
4,452,856
-
Share change
-
+3,192,966
-
Total reported value
-
$1,286,473
-
Price per share
-
$0.29
-
Number of holders
-
21
-
Value change
-
+$872,091
-
Number of buys
-
10
-
Number of sells
-
6
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) as of Q4 2025
As of 31 Dec 2025,
Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,452,856 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Cresset Asset Management, LLC, Warberg Asset Management LLC, Palo Alto Investors LP, HighTower Advisors, LLC, JANE STREET GROUP, LLC, SmartHarvest Portfolios, LLC, CWA Asset Management Group, LLC, XTX Topco Ltd, and UBS Group AG.
This page lists
21
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.